Leerink Partners Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $40
Express News | Veracyte Inc : Leerink Partners Raises Target Price to $40 From $35
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
Veracyte Started at Buy by UBS, MRD Platform Cited
UBS Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $43
Breaking Down Veracyte: 4 Analysts Share Their Views
Veracyte Analyst Ratings
Guggenheim Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $40
Estimating The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
Vanguard Group Inc's Strategic Acquisition of Veracyte Inc Shares
Veracyte Hikes on Cancer Test Data
Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024
Scotiabank Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $40
Scotiabank Sticks to Their Buy Rating for Veracyte (VCYT)
Express News | Veracyte Inc : Scotiabank Raises Target Price to $40 From $37
Veracyte Director Jones Sells Over $182,000 in Company Stock
Express News | Veracyte Inc - Data Support Company's Plan to Expand Decipher Prostate Test to Patients With Metastatic Disease
New Data Presented at ESMO 2024 Show That Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients With Metastatic Prostate Cancer
Insider Sale: Chief Commercial Officer-CLIA John Leite Sells Shares of Veracyte Inc (VCYT)